Gilead Sciences' ascent to the upper echelon of biotech centered around one very savvy acquisition that launched an HIV franchise. Shortly after the turn of the century, Gilead Sciences took a ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...